Review



effect than ect  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress effect than ect
    Network geometry for the comparisons of <t>A</t> <t>Shoulder</t> Disability Index and B Shoulder Pain Score. TT, traditional training; <t>ECT,</t> eccentric strengthening training; CST, concentric strengthening training; SFT, scapula-focused training; MCE, motor control exercise; LLT, low-load training. The size of each node corresponds to the number of participants in that intervention arm. The width of the connecting lines represents the number of direct comparisons between intervention arms
    Effect Than Ect, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/effect than ect/product/MedChemExpress
    Average 93 stars, based on 9 article reviews
    effect than ect - by Bioz Stars, 2026-02
    93/100 stars

    Images

    1) Product Images from "Effects of seven types of exercise in the treatment of rotator cuff-related shoulder pain (RCRSP): a systematic review and Bayesian network meta-analysis"

    Article Title: Effects of seven types of exercise in the treatment of rotator cuff-related shoulder pain (RCRSP): a systematic review and Bayesian network meta-analysis

    Journal: Journal of Orthopaedic Surgery and Research

    doi: 10.1186/s13018-025-06514-4

    Network geometry for the comparisons of A Shoulder Disability Index and B Shoulder Pain Score. TT, traditional training; ECT, eccentric strengthening training; CST, concentric strengthening training; SFT, scapula-focused training; MCE, motor control exercise; LLT, low-load training. The size of each node corresponds to the number of participants in that intervention arm. The width of the connecting lines represents the number of direct comparisons between intervention arms
    Figure Legend Snippet: Network geometry for the comparisons of A Shoulder Disability Index and B Shoulder Pain Score. TT, traditional training; ECT, eccentric strengthening training; CST, concentric strengthening training; SFT, scapula-focused training; MCE, motor control exercise; LLT, low-load training. The size of each node corresponds to the number of participants in that intervention arm. The width of the connecting lines represents the number of direct comparisons between intervention arms

    Techniques Used: Control

    Surface Under the Cumulative Ranking Curve (SUCRA) for Exercise Interventions. A Shoulder disability index. B Shoulder pain score. Higher SUCRA values indicate a higher probability of being the most effective intervention. CST, Concentric Strengthening Training; ECT, Eccentric Strengthening Training; HLT, High-Load Training; LLT, Low-Load Training; MCE, Motor Control Exercise; SFT, Scapula-Focused Training; TT, Traditional Training
    Figure Legend Snippet: Surface Under the Cumulative Ranking Curve (SUCRA) for Exercise Interventions. A Shoulder disability index. B Shoulder pain score. Higher SUCRA values indicate a higher probability of being the most effective intervention. CST, Concentric Strengthening Training; ECT, Eccentric Strengthening Training; HLT, High-Load Training; LLT, Low-Load Training; MCE, Motor Control Exercise; SFT, Scapula-Focused Training; TT, Traditional Training

    Techniques Used: Control

    Funnel plots assessing potential publication bias for each outcome. A Shoulder Disability Index. B Shoulder Pain Score. Symmetrical distribution of the plotted comparisons suggests a low risk of publication bias. CST, Concentric Strengthening Training; ECT, Eccentric Strengthening Training; HLT, High-Load Training; LLT, Low-Load Training; MCE, Motor Control Exercise; SFT, Scapula-Focused Training; TT, Traditional Training
    Figure Legend Snippet: Funnel plots assessing potential publication bias for each outcome. A Shoulder Disability Index. B Shoulder Pain Score. Symmetrical distribution of the plotted comparisons suggests a low risk of publication bias. CST, Concentric Strengthening Training; ECT, Eccentric Strengthening Training; HLT, High-Load Training; LLT, Low-Load Training; MCE, Motor Control Exercise; SFT, Scapula-Focused Training; TT, Traditional Training

    Techniques Used: Control



    Similar Products

    effect than ect  (MedChemExpress)
    93
    MedChemExpress effect than ect
    Network geometry for the comparisons of <t>A</t> <t>Shoulder</t> Disability Index and B Shoulder Pain Score. TT, traditional training; <t>ECT,</t> eccentric strengthening training; CST, concentric strengthening training; SFT, scapula-focused training; MCE, motor control exercise; LLT, low-load training. The size of each node corresponds to the number of participants in that intervention arm. The width of the connecting lines represents the number of direct comparisons between intervention arms
    Effect Than Ect, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/effect than ect/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    effect than ect - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    mnk inhibitor ect  (MedChemExpress)
    93
    MedChemExpress mnk inhibitor ect
    KRAS G12C inhibitors upregulate ALDH1A1 expression by inhibiting GTF2I phosphorylation at S784 via ERK and impair nuclear translocation . (A) qRT-PCR and WB showed the ALDH1A1 expression alteration following the treatment of sotorasib or adagrasib (IC50, 72 h), withdrawal of the inhibitors (72 h), and retreated with them (IC50, 72 h). (n = 3) (B) qRT-PCR and WB showed the ALDH1A1 expression decreased when treated with KRAS G12C inhibitors (IC50) or ERK inhibitor SCH7 72984 (IC50 = 50 nM), not AKT inhibitor MK-2206 (IC50 = 100 nM) for 72 h. (n = 3) (C) Genome-wide data of ALDH1A1 from the ENCODE database showed the ZNF784 and GTF2I binding peak in the promotor region close to the transcription start site (TSS) of ALDH1A1 after screening via DNA pull down with MS. (D – E) qRT-PCR (D) and WB (E) showed ZNF384, GTF2I, ALDH1A1 expression altered upon knockdown (KD) by three siRNAs together in MIAPACA2 and H2122 cells (n = 3). ALDH1A1 expression increased only in GTF2I -KD cells. (F) Dual-luciferase assays showed the fluorescence intensity of GTF2I -NC and KD in ALDH1A1-WT or mutated type of the promoter region in the two cell lines (n = 3). (G) qRT-PCR and WB showed no alteration of ALDH1A1 expression level when treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h in two cell lines (n = 3). (H) qRT-PCR showed ALDH1A1 expression altered upon treatment with inhibitors sotorasib (IC50), adagrasib (IC50), BRD7389 (for RSK, IC50 = 1.5 μM), RMM-46 (for MSK, IC50 = 200 nM), <t>and</t> <t>ECT-206</t> (for MNK, IC50 = 70 nM) for 72 h in MIAPACA2 and H2122 cells (n = 3). ALDH1A1 expression increased when treated with KRAS inhibitors and RMM-46. ( I-J ) In vitro phosphorylation assay validated decrease of p -ERK, p -GTF2I at S784 and upregulated expression of ALDH1A1 in two cell lines treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h, and p -MSK, p -GTF2I at S784 and upregulated expression of ALDH1A1 with RMM-46, while ERK, MSK and GTF2I showed no difference (I) The alteration were abolished in GTF2I–S784A (a phospho-deficient mutant) and GTF2I–S784D (a phospho-mimetic mutant) group (J). (K) The immunofluorescence images and fluorescence intensity of each diagonal line in the selected area showed the GTFI location in MIAPACA2 and H2122 cells treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h (scale bars, 20 μm). Data were analyzed by Student's t-test and were presented by mean ± SD.
    Mnk Inhibitor Ect, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mnk inhibitor ect/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    mnk inhibitor ect - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    magnetocaloric e ect  (MedChemExpress)
    93
    MedChemExpress magnetocaloric e ect
    KRAS G12C inhibitors upregulate ALDH1A1 expression by inhibiting GTF2I phosphorylation at S784 via ERK and impair nuclear translocation . (A) qRT-PCR and WB showed the ALDH1A1 expression alteration following the treatment of sotorasib or adagrasib (IC50, 72 h), withdrawal of the inhibitors (72 h), and retreated with them (IC50, 72 h). (n = 3) (B) qRT-PCR and WB showed the ALDH1A1 expression decreased when treated with KRAS G12C inhibitors (IC50) or ERK inhibitor SCH7 72984 (IC50 = 50 nM), not AKT inhibitor MK-2206 (IC50 = 100 nM) for 72 h. (n = 3) (C) Genome-wide data of ALDH1A1 from the ENCODE database showed the ZNF784 and GTF2I binding peak in the promotor region close to the transcription start site (TSS) of ALDH1A1 after screening via DNA pull down with MS. (D – E) qRT-PCR (D) and WB (E) showed ZNF384, GTF2I, ALDH1A1 expression altered upon knockdown (KD) by three siRNAs together in MIAPACA2 and H2122 cells (n = 3). ALDH1A1 expression increased only in GTF2I -KD cells. (F) Dual-luciferase assays showed the fluorescence intensity of GTF2I -NC and KD in ALDH1A1-WT or mutated type of the promoter region in the two cell lines (n = 3). (G) qRT-PCR and WB showed no alteration of ALDH1A1 expression level when treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h in two cell lines (n = 3). (H) qRT-PCR showed ALDH1A1 expression altered upon treatment with inhibitors sotorasib (IC50), adagrasib (IC50), BRD7389 (for RSK, IC50 = 1.5 μM), RMM-46 (for MSK, IC50 = 200 nM), <t>and</t> <t>ECT-206</t> (for MNK, IC50 = 70 nM) for 72 h in MIAPACA2 and H2122 cells (n = 3). ALDH1A1 expression increased when treated with KRAS inhibitors and RMM-46. ( I-J ) In vitro phosphorylation assay validated decrease of p -ERK, p -GTF2I at S784 and upregulated expression of ALDH1A1 in two cell lines treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h, and p -MSK, p -GTF2I at S784 and upregulated expression of ALDH1A1 with RMM-46, while ERK, MSK and GTF2I showed no difference (I) The alteration were abolished in GTF2I–S784A (a phospho-deficient mutant) and GTF2I–S784D (a phospho-mimetic mutant) group (J). (K) The immunofluorescence images and fluorescence intensity of each diagonal line in the selected area showed the GTFI location in MIAPACA2 and H2122 cells treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h (scale bars, 20 μm). Data were analyzed by Student's t-test and were presented by mean ± SD.
    Magnetocaloric E Ect, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/magnetocaloric e ect/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    magnetocaloric e ect - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    ectoine biosynthesis  (MedChemExpress)
    93
    MedChemExpress ectoine biosynthesis
    KRAS G12C inhibitors upregulate ALDH1A1 expression by inhibiting GTF2I phosphorylation at S784 via ERK and impair nuclear translocation . (A) qRT-PCR and WB showed the ALDH1A1 expression alteration following the treatment of sotorasib or adagrasib (IC50, 72 h), withdrawal of the inhibitors (72 h), and retreated with them (IC50, 72 h). (n = 3) (B) qRT-PCR and WB showed the ALDH1A1 expression decreased when treated with KRAS G12C inhibitors (IC50) or ERK inhibitor SCH7 72984 (IC50 = 50 nM), not AKT inhibitor MK-2206 (IC50 = 100 nM) for 72 h. (n = 3) (C) Genome-wide data of ALDH1A1 from the ENCODE database showed the ZNF784 and GTF2I binding peak in the promotor region close to the transcription start site (TSS) of ALDH1A1 after screening via DNA pull down with MS. (D – E) qRT-PCR (D) and WB (E) showed ZNF384, GTF2I, ALDH1A1 expression altered upon knockdown (KD) by three siRNAs together in MIAPACA2 and H2122 cells (n = 3). ALDH1A1 expression increased only in GTF2I -KD cells. (F) Dual-luciferase assays showed the fluorescence intensity of GTF2I -NC and KD in ALDH1A1-WT or mutated type of the promoter region in the two cell lines (n = 3). (G) qRT-PCR and WB showed no alteration of ALDH1A1 expression level when treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h in two cell lines (n = 3). (H) qRT-PCR showed ALDH1A1 expression altered upon treatment with inhibitors sotorasib (IC50), adagrasib (IC50), BRD7389 (for RSK, IC50 = 1.5 μM), RMM-46 (for MSK, IC50 = 200 nM), <t>and</t> <t>ECT-206</t> (for MNK, IC50 = 70 nM) for 72 h in MIAPACA2 and H2122 cells (n = 3). ALDH1A1 expression increased when treated with KRAS inhibitors and RMM-46. ( I-J ) In vitro phosphorylation assay validated decrease of p -ERK, p -GTF2I at S784 and upregulated expression of ALDH1A1 in two cell lines treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h, and p -MSK, p -GTF2I at S784 and upregulated expression of ALDH1A1 with RMM-46, while ERK, MSK and GTF2I showed no difference (I) The alteration were abolished in GTF2I–S784A (a phospho-deficient mutant) and GTF2I–S784D (a phospho-mimetic mutant) group (J). (K) The immunofluorescence images and fluorescence intensity of each diagonal line in the selected area showed the GTFI location in MIAPACA2 and H2122 cells treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h (scale bars, 20 μm). Data were analyzed by Student's t-test and were presented by mean ± SD.
    Ectoine Biosynthesis, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ectoine biosynthesis/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    ectoine biosynthesis - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    a gene cluster encoding ectoine biosynthesis proteins  (MedChemExpress)
    93
    MedChemExpress a gene cluster encoding ectoine biosynthesis proteins
    KRAS G12C inhibitors upregulate ALDH1A1 expression by inhibiting GTF2I phosphorylation at S784 via ERK and impair nuclear translocation . (A) qRT-PCR and WB showed the ALDH1A1 expression alteration following the treatment of sotorasib or adagrasib (IC50, 72 h), withdrawal of the inhibitors (72 h), and retreated with them (IC50, 72 h). (n = 3) (B) qRT-PCR and WB showed the ALDH1A1 expression decreased when treated with KRAS G12C inhibitors (IC50) or ERK inhibitor SCH7 72984 (IC50 = 50 nM), not AKT inhibitor MK-2206 (IC50 = 100 nM) for 72 h. (n = 3) (C) Genome-wide data of ALDH1A1 from the ENCODE database showed the ZNF784 and GTF2I binding peak in the promotor region close to the transcription start site (TSS) of ALDH1A1 after screening via DNA pull down with MS. (D – E) qRT-PCR (D) and WB (E) showed ZNF384, GTF2I, ALDH1A1 expression altered upon knockdown (KD) by three siRNAs together in MIAPACA2 and H2122 cells (n = 3). ALDH1A1 expression increased only in GTF2I -KD cells. (F) Dual-luciferase assays showed the fluorescence intensity of GTF2I -NC and KD in ALDH1A1-WT or mutated type of the promoter region in the two cell lines (n = 3). (G) qRT-PCR and WB showed no alteration of ALDH1A1 expression level when treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h in two cell lines (n = 3). (H) qRT-PCR showed ALDH1A1 expression altered upon treatment with inhibitors sotorasib (IC50), adagrasib (IC50), BRD7389 (for RSK, IC50 = 1.5 μM), RMM-46 (for MSK, IC50 = 200 nM), <t>and</t> <t>ECT-206</t> (for MNK, IC50 = 70 nM) for 72 h in MIAPACA2 and H2122 cells (n = 3). ALDH1A1 expression increased when treated with KRAS inhibitors and RMM-46. ( I-J ) In vitro phosphorylation assay validated decrease of p -ERK, p -GTF2I at S784 and upregulated expression of ALDH1A1 in two cell lines treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h, and p -MSK, p -GTF2I at S784 and upregulated expression of ALDH1A1 with RMM-46, while ERK, MSK and GTF2I showed no difference (I) The alteration were abolished in GTF2I–S784A (a phospho-deficient mutant) and GTF2I–S784D (a phospho-mimetic mutant) group (J). (K) The immunofluorescence images and fluorescence intensity of each diagonal line in the selected area showed the GTFI location in MIAPACA2 and H2122 cells treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h (scale bars, 20 μm). Data were analyzed by Student's t-test and were presented by mean ± SD.
    A Gene Cluster Encoding Ectoine Biosynthesis Proteins, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a gene cluster encoding ectoine biosynthesis proteins/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    a gene cluster encoding ectoine biosynthesis proteins - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    e magnetocaloric e ect  (MedChemExpress)
    93
    MedChemExpress e magnetocaloric e ect
    KRAS G12C inhibitors upregulate ALDH1A1 expression by inhibiting GTF2I phosphorylation at S784 via ERK and impair nuclear translocation . (A) qRT-PCR and WB showed the ALDH1A1 expression alteration following the treatment of sotorasib or adagrasib (IC50, 72 h), withdrawal of the inhibitors (72 h), and retreated with them (IC50, 72 h). (n = 3) (B) qRT-PCR and WB showed the ALDH1A1 expression decreased when treated with KRAS G12C inhibitors (IC50) or ERK inhibitor SCH7 72984 (IC50 = 50 nM), not AKT inhibitor MK-2206 (IC50 = 100 nM) for 72 h. (n = 3) (C) Genome-wide data of ALDH1A1 from the ENCODE database showed the ZNF784 and GTF2I binding peak in the promotor region close to the transcription start site (TSS) of ALDH1A1 after screening via DNA pull down with MS. (D – E) qRT-PCR (D) and WB (E) showed ZNF384, GTF2I, ALDH1A1 expression altered upon knockdown (KD) by three siRNAs together in MIAPACA2 and H2122 cells (n = 3). ALDH1A1 expression increased only in GTF2I -KD cells. (F) Dual-luciferase assays showed the fluorescence intensity of GTF2I -NC and KD in ALDH1A1-WT or mutated type of the promoter region in the two cell lines (n = 3). (G) qRT-PCR and WB showed no alteration of ALDH1A1 expression level when treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h in two cell lines (n = 3). (H) qRT-PCR showed ALDH1A1 expression altered upon treatment with inhibitors sotorasib (IC50), adagrasib (IC50), BRD7389 (for RSK, IC50 = 1.5 μM), RMM-46 (for MSK, IC50 = 200 nM), <t>and</t> <t>ECT-206</t> (for MNK, IC50 = 70 nM) for 72 h in MIAPACA2 and H2122 cells (n = 3). ALDH1A1 expression increased when treated with KRAS inhibitors and RMM-46. ( I-J ) In vitro phosphorylation assay validated decrease of p -ERK, p -GTF2I at S784 and upregulated expression of ALDH1A1 in two cell lines treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h, and p -MSK, p -GTF2I at S784 and upregulated expression of ALDH1A1 with RMM-46, while ERK, MSK and GTF2I showed no difference (I) The alteration were abolished in GTF2I–S784A (a phospho-deficient mutant) and GTF2I–S784D (a phospho-mimetic mutant) group (J). (K) The immunofluorescence images and fluorescence intensity of each diagonal line in the selected area showed the GTFI location in MIAPACA2 and H2122 cells treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h (scale bars, 20 μm). Data were analyzed by Student's t-test and were presented by mean ± SD.
    E Magnetocaloric E Ect, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/e magnetocaloric e ect/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    e magnetocaloric e ect - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Network geometry for the comparisons of A Shoulder Disability Index and B Shoulder Pain Score. TT, traditional training; ECT, eccentric strengthening training; CST, concentric strengthening training; SFT, scapula-focused training; MCE, motor control exercise; LLT, low-load training. The size of each node corresponds to the number of participants in that intervention arm. The width of the connecting lines represents the number of direct comparisons between intervention arms

    Journal: Journal of Orthopaedic Surgery and Research

    Article Title: Effects of seven types of exercise in the treatment of rotator cuff-related shoulder pain (RCRSP): a systematic review and Bayesian network meta-analysis

    doi: 10.1186/s13018-025-06514-4

    Figure Lengend Snippet: Network geometry for the comparisons of A Shoulder Disability Index and B Shoulder Pain Score. TT, traditional training; ECT, eccentric strengthening training; CST, concentric strengthening training; SFT, scapula-focused training; MCE, motor control exercise; LLT, low-load training. The size of each node corresponds to the number of participants in that intervention arm. The width of the connecting lines represents the number of direct comparisons between intervention arms

    Article Snippet: For the Shoulder Disability Index, CST showed a significantly greater effect than ECT (SMD = 3.49; 95%CrI [0.28, 6.7]), HLT (SMD = 23.87; 95%CrI [4.81, 42.92]), LLT (SMD = 22.90; 95%CrI [3.72, 42.1]), MCE (SMD = 12.04; 95%CrI [5.21, 18.88]), SFT (SMD = 12.65; 95%CrI [5.83, 19.4]), and TT (SMD = 5.91; 95%CrI [0.64, 11.17]), and the relative effect of ECT was greater than HLT (SMD = 20.38; 95%CrI [1.6, 39.14]), LLT (SMD = 19.40; 95%CrI [0.49, 38.35]), MCE (SMD = 8.55; 95%CrI [2.52, 14.55]) and SFT (SMD = 9.16; 95%CrI [3.19, 15.11]).

    Techniques: Control

    Surface Under the Cumulative Ranking Curve (SUCRA) for Exercise Interventions. A Shoulder disability index. B Shoulder pain score. Higher SUCRA values indicate a higher probability of being the most effective intervention. CST, Concentric Strengthening Training; ECT, Eccentric Strengthening Training; HLT, High-Load Training; LLT, Low-Load Training; MCE, Motor Control Exercise; SFT, Scapula-Focused Training; TT, Traditional Training

    Journal: Journal of Orthopaedic Surgery and Research

    Article Title: Effects of seven types of exercise in the treatment of rotator cuff-related shoulder pain (RCRSP): a systematic review and Bayesian network meta-analysis

    doi: 10.1186/s13018-025-06514-4

    Figure Lengend Snippet: Surface Under the Cumulative Ranking Curve (SUCRA) for Exercise Interventions. A Shoulder disability index. B Shoulder pain score. Higher SUCRA values indicate a higher probability of being the most effective intervention. CST, Concentric Strengthening Training; ECT, Eccentric Strengthening Training; HLT, High-Load Training; LLT, Low-Load Training; MCE, Motor Control Exercise; SFT, Scapula-Focused Training; TT, Traditional Training

    Article Snippet: For the Shoulder Disability Index, CST showed a significantly greater effect than ECT (SMD = 3.49; 95%CrI [0.28, 6.7]), HLT (SMD = 23.87; 95%CrI [4.81, 42.92]), LLT (SMD = 22.90; 95%CrI [3.72, 42.1]), MCE (SMD = 12.04; 95%CrI [5.21, 18.88]), SFT (SMD = 12.65; 95%CrI [5.83, 19.4]), and TT (SMD = 5.91; 95%CrI [0.64, 11.17]), and the relative effect of ECT was greater than HLT (SMD = 20.38; 95%CrI [1.6, 39.14]), LLT (SMD = 19.40; 95%CrI [0.49, 38.35]), MCE (SMD = 8.55; 95%CrI [2.52, 14.55]) and SFT (SMD = 9.16; 95%CrI [3.19, 15.11]).

    Techniques: Control

    Funnel plots assessing potential publication bias for each outcome. A Shoulder Disability Index. B Shoulder Pain Score. Symmetrical distribution of the plotted comparisons suggests a low risk of publication bias. CST, Concentric Strengthening Training; ECT, Eccentric Strengthening Training; HLT, High-Load Training; LLT, Low-Load Training; MCE, Motor Control Exercise; SFT, Scapula-Focused Training; TT, Traditional Training

    Journal: Journal of Orthopaedic Surgery and Research

    Article Title: Effects of seven types of exercise in the treatment of rotator cuff-related shoulder pain (RCRSP): a systematic review and Bayesian network meta-analysis

    doi: 10.1186/s13018-025-06514-4

    Figure Lengend Snippet: Funnel plots assessing potential publication bias for each outcome. A Shoulder Disability Index. B Shoulder Pain Score. Symmetrical distribution of the plotted comparisons suggests a low risk of publication bias. CST, Concentric Strengthening Training; ECT, Eccentric Strengthening Training; HLT, High-Load Training; LLT, Low-Load Training; MCE, Motor Control Exercise; SFT, Scapula-Focused Training; TT, Traditional Training

    Article Snippet: For the Shoulder Disability Index, CST showed a significantly greater effect than ECT (SMD = 3.49; 95%CrI [0.28, 6.7]), HLT (SMD = 23.87; 95%CrI [4.81, 42.92]), LLT (SMD = 22.90; 95%CrI [3.72, 42.1]), MCE (SMD = 12.04; 95%CrI [5.21, 18.88]), SFT (SMD = 12.65; 95%CrI [5.83, 19.4]), and TT (SMD = 5.91; 95%CrI [0.64, 11.17]), and the relative effect of ECT was greater than HLT (SMD = 20.38; 95%CrI [1.6, 39.14]), LLT (SMD = 19.40; 95%CrI [0.49, 38.35]), MCE (SMD = 8.55; 95%CrI [2.52, 14.55]) and SFT (SMD = 9.16; 95%CrI [3.19, 15.11]).

    Techniques: Control

    KRAS G12C inhibitors upregulate ALDH1A1 expression by inhibiting GTF2I phosphorylation at S784 via ERK and impair nuclear translocation . (A) qRT-PCR and WB showed the ALDH1A1 expression alteration following the treatment of sotorasib or adagrasib (IC50, 72 h), withdrawal of the inhibitors (72 h), and retreated with them (IC50, 72 h). (n = 3) (B) qRT-PCR and WB showed the ALDH1A1 expression decreased when treated with KRAS G12C inhibitors (IC50) or ERK inhibitor SCH7 72984 (IC50 = 50 nM), not AKT inhibitor MK-2206 (IC50 = 100 nM) for 72 h. (n = 3) (C) Genome-wide data of ALDH1A1 from the ENCODE database showed the ZNF784 and GTF2I binding peak in the promotor region close to the transcription start site (TSS) of ALDH1A1 after screening via DNA pull down with MS. (D – E) qRT-PCR (D) and WB (E) showed ZNF384, GTF2I, ALDH1A1 expression altered upon knockdown (KD) by three siRNAs together in MIAPACA2 and H2122 cells (n = 3). ALDH1A1 expression increased only in GTF2I -KD cells. (F) Dual-luciferase assays showed the fluorescence intensity of GTF2I -NC and KD in ALDH1A1-WT or mutated type of the promoter region in the two cell lines (n = 3). (G) qRT-PCR and WB showed no alteration of ALDH1A1 expression level when treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h in two cell lines (n = 3). (H) qRT-PCR showed ALDH1A1 expression altered upon treatment with inhibitors sotorasib (IC50), adagrasib (IC50), BRD7389 (for RSK, IC50 = 1.5 μM), RMM-46 (for MSK, IC50 = 200 nM), and ECT-206 (for MNK, IC50 = 70 nM) for 72 h in MIAPACA2 and H2122 cells (n = 3). ALDH1A1 expression increased when treated with KRAS inhibitors and RMM-46. ( I-J ) In vitro phosphorylation assay validated decrease of p -ERK, p -GTF2I at S784 and upregulated expression of ALDH1A1 in two cell lines treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h, and p -MSK, p -GTF2I at S784 and upregulated expression of ALDH1A1 with RMM-46, while ERK, MSK and GTF2I showed no difference (I) The alteration were abolished in GTF2I–S784A (a phospho-deficient mutant) and GTF2I–S784D (a phospho-mimetic mutant) group (J). (K) The immunofluorescence images and fluorescence intensity of each diagonal line in the selected area showed the GTFI location in MIAPACA2 and H2122 cells treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h (scale bars, 20 μm). Data were analyzed by Student's t-test and were presented by mean ± SD.

    Journal: Redox Biology

    Article Title: Targeting ALDH1A1 to enhance the efficacy of KRAS-targeted therapy through ferroptosis

    doi: 10.1016/j.redox.2024.103361

    Figure Lengend Snippet: KRAS G12C inhibitors upregulate ALDH1A1 expression by inhibiting GTF2I phosphorylation at S784 via ERK and impair nuclear translocation . (A) qRT-PCR and WB showed the ALDH1A1 expression alteration following the treatment of sotorasib or adagrasib (IC50, 72 h), withdrawal of the inhibitors (72 h), and retreated with them (IC50, 72 h). (n = 3) (B) qRT-PCR and WB showed the ALDH1A1 expression decreased when treated with KRAS G12C inhibitors (IC50) or ERK inhibitor SCH7 72984 (IC50 = 50 nM), not AKT inhibitor MK-2206 (IC50 = 100 nM) for 72 h. (n = 3) (C) Genome-wide data of ALDH1A1 from the ENCODE database showed the ZNF784 and GTF2I binding peak in the promotor region close to the transcription start site (TSS) of ALDH1A1 after screening via DNA pull down with MS. (D – E) qRT-PCR (D) and WB (E) showed ZNF384, GTF2I, ALDH1A1 expression altered upon knockdown (KD) by three siRNAs together in MIAPACA2 and H2122 cells (n = 3). ALDH1A1 expression increased only in GTF2I -KD cells. (F) Dual-luciferase assays showed the fluorescence intensity of GTF2I -NC and KD in ALDH1A1-WT or mutated type of the promoter region in the two cell lines (n = 3). (G) qRT-PCR and WB showed no alteration of ALDH1A1 expression level when treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h in two cell lines (n = 3). (H) qRT-PCR showed ALDH1A1 expression altered upon treatment with inhibitors sotorasib (IC50), adagrasib (IC50), BRD7389 (for RSK, IC50 = 1.5 μM), RMM-46 (for MSK, IC50 = 200 nM), and ECT-206 (for MNK, IC50 = 70 nM) for 72 h in MIAPACA2 and H2122 cells (n = 3). ALDH1A1 expression increased when treated with KRAS inhibitors and RMM-46. ( I-J ) In vitro phosphorylation assay validated decrease of p -ERK, p -GTF2I at S784 and upregulated expression of ALDH1A1 in two cell lines treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h, and p -MSK, p -GTF2I at S784 and upregulated expression of ALDH1A1 with RMM-46, while ERK, MSK and GTF2I showed no difference (I) The alteration were abolished in GTF2I–S784A (a phospho-deficient mutant) and GTF2I–S784D (a phospho-mimetic mutant) group (J). (K) The immunofluorescence images and fluorescence intensity of each diagonal line in the selected area showed the GTFI location in MIAPACA2 and H2122 cells treated with sotorasib, adagrasib or SCH7 72984 (IC50) for 72 h (scale bars, 20 μm). Data were analyzed by Student's t-test and were presented by mean ± SD.

    Article Snippet: Pan-KRAS inhibitor BI-2493, RARA inhibitor AGN193109, and MNK inhibitor ECT-206 were purchased from MedChemExpress (Shanghai, China).

    Techniques: Expressing, Phospho-proteomics, Translocation Assay, Quantitative RT-PCR, Genome Wide, Binding Assay, Knockdown, Luciferase, Fluorescence, In Vitro, Mutagenesis, Immunofluorescence